@xconomy.com 10 months ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com 10 months ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com 12 months ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com 1 year ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com 1 year ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com 1 year ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com 1 year ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com 1 year ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com 1 year ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com 1 year ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com 1 year ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com 1 year ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com 1 year ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com 1 year ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com 1 year ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com 1 year ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way